Idorsia Ltd (SIX: IDIA) announced the publication of a new analysis from the landmark Phase 3 PRECISION study in Hypertension titled “Aprocitentan in Patients with Chronic Kidney Disease and Resistant ...

New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of ...

Credit: Getty Images. The PRECISION study included adults with uncontrolled blood pressure despite at least 3 background antihypertensive medications. Positive topline results were announced from a ...

The US Food and Drug Administration has approved aprocitentan (Tryvio) for the treatment of high blood pressure, according to an announcement today from Idorsia Pharmaceuticals, the drug’s ...

The FDA has approved aprocitentan (Tryvio), making it the first endothelin receptor antagonist for the treatment of high blood pressure (BP), Idorsia Pharmaceuticals announced on Wednesday. The ...

TRYVIO is not approved for use at a 25 mg dose. The efficacy for the 25 mg aprocitentan dose as measured in the primary end point of change in sitting SBP (SiSBP) from baseline to Week 4 in part 1, ...

Blocking the endothelin pathway could represent a new mode of action to lower blood pressure in resistant hypertension, according to investigators. Aprocitentan, a dual endothelin receptor A and B ...

Idorsia secures $350 million in funding through a collaboration agreement with Viatris, solving immediate liquidity concerns. FDA approves Idorsia's Aprocitentan drug. There is a potential peak sales ...

(RTTNews) - Swiss biotech firm Idorsia Ltd announced Wednesday that it has entered into exclusive negotiations with an undisclosed party for the global rights to aprocitentan, a once-daily, orally ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

A quartet of new medications may improve care of patients with hypertension, urinary tract infections (UTIs), hot flashes, and liver disease, said Gerald W. Smetana, MD, professor of medicine at ...

New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a ...